Literature DB >> 29667722

Acute myelogenous leukemia in adolescents and young adults.

Ursula Creutzig1, Matthew A Kutny2, Ronald Barr3, Richard F Schlenk4, Raul C Ribeiro5.   

Abstract

The incidence of acute myelogenous leukemia (AML) increases progressively with age. Favorable genetic mutations are most prevalent in children, and unfavorable profiles increase proportionately in adolescents and young adults (AYA) and into later adulthood. Survival rates of AYA have improved over recent decades to 50-60%, but their accrual to clinical trials remains poor. In contrast to AYA with acute lymphoblastic leukemia, the prognostic benefit for AYA with AML enrolled in pediatric compared with adult trials is minor and only seen when different protocols are used. The distinctive needs of AYA, including intensive psychological services, call for their treatment within specialized centers that offer complex supportive care.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  acute myelogenous leukemia (AML); adolescents and young adults (AYA); clinical trials; prognosis; survival

Mesh：

Year:  2018        PMID： 29667722      PMCID： PMC6105504          DOI： 10.1002/pbc.27089

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  73 in total

Review 1.  Endocrine late effects after bone marrow transplant.

Authors:  Bernadette M D Brennan; Stephen M Shalet
Journal:  Br J Haematol       Date:  2002-07       Impact factor: 6.998

2.  Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.

Authors:  Can-Lan Sun; Liton Francisco; Toana Kawashima; Wendy Leisenring; Leslie L Robison; K Scott Baker; Daniel J Weisdorf; Stephen J Forman; Smita Bhatia
Journal:  Blood       Date:  2010-07-23       Impact factor: 22.113

3.  NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: state of the science, future directions.

Authors:  K Scott Baker; Smita Bhatia; Nancy Bunin; Michael Nieder; Christopher C Dvorak; Lillian Sung; Jean E Sanders; Joanne Kurtzberg; Michael A Pulsipher
Journal:  Biol Blood Marrow Transplant       Date:  2011-06-30       Impact factor: 5.742

4.  Racial and ethnic disparities in the survival of adolescents and young adults with acute myeloid leukemia: a retrospective study using the US National Cancer Data Base.

Authors:  Urshila Durani; Ronald S Go
Journal:  Leuk Lymphoma       Date:  2016-11-03

5.  Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia.

Authors:  Gwendolyn Ho; Brian A Jonas; Qian Li; Ann Brunson; Ted Wun; Theresa H M Keegan
Journal:  Br J Haematol       Date:  2017-04-17       Impact factor: 6.998

6.  Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.

Authors:  Ursula Creutzig; Martin Zimmermann; Jean-Pierre Bourquin; Michael N Dworzak; Gudrun Fleischhack; Norbert Graf; Thomas Klingebiel; Bernhard Kremens; Thomas Lehrnbecher; Christine von Neuhoff; Jörg Ritter; Annette Sander; André Schrauder; Arend von Stackelberg; Jan Starý; Dirk Reinhardt
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

7.  6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.

Authors:  Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Christa Fonatsch; Helmut Löffler; Torsten Haferlach; Wolf-Dieter Ludwig; Georg Maschmeyer; Peter Staib; Carlo Aul; Andreas Gruneisen; Eva Lengfelder; Norbert Frickhofen; Wolfgang Kern; Hubert L Serve; Rolf M Mesters; Maria Cristina Sauerland; Achim Heinecke
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

8.  Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group.

Authors:  Jason Canner; Todd A Alonzo; Janet Franklin; David R Freyer; Alan Gamis; Robert B Gerbing; Beverly J Lange; Soheil Meshinchi; William G Woods; John Perentesis; John Horan
Journal:  Cancer       Date:  2013-09-19       Impact factor: 6.860

9.  Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).

Authors:  Gabriele Nagel; D Weber; E Fromm; S Erhardt; M Lübbert; W Fiedler; T Kindler; J Krauter; P Brossart; A Kündgen; H R Salih; J Westermann; G Wulf; B Hertenstein; M Wattad; K Götze; D Kraemer; T Heinicke; M Girschikofsky; H G Derigs; H A Horst; C Rudolph; M Heuser; G Göhring; V Teleanu; L Bullinger; F Thol; V I Gaidzik; P Paschka; K Döhner; A Ganser; Hartmut Döhner; R F Schlenk
Journal:  Ann Hematol       Date:  2017-10-31       Impact factor: 3.673

10.  The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey.

Authors:  Emmanouil Saloustros; Daniel P Stark; Kyriaki Michailidou; Giannis Mountzios; Laurence Brugieres; Fedro Alessandro Peccatori; Svetlana Jezdic; Samira Essiaf; Jean-Yves Douillard; Stefan Bielack
Journal:  ESMO Open       Date:  2017-09-08
View more
  14 in total

1.  Psychosocial Experiences of Young Adults Diagnosed With Acute Leukemia During Hospitalization for Induction Chemotherapy Treatment.

Authors:  Tara A Albrecht; Jessica Keim-Malpass; Michael Boyiadzis; Margaret Rosenzweig
Journal:  J Hosp Palliat Nurs       Date:  2019-04       Impact factor: 1.918

2.  Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience.

Authors:  Jeffrey R Andolina; Yi-Cheng Wang; Lingyun Ji; David R Freyer; John E Levine; Michael A Pulsipher; Alan S Gamis; Richard Aplenc; Michael E Roth; Lauren Harrison; Mitchell S Cairo
Journal:  Bone Marrow Transplant       Date:  2022-01-06       Impact factor: 5.174

3.  Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis.

Authors:  Amy M Berkman; Clark R Andersen; Branko Cuglievan; David C McCall; Philip J Lupo; Susan K Parsons; Courtney D DiNardo; Nicholas J Short; Nitin Jain; Tapan M Kadia; J A Livingston; Michael E Roth
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-06-01       Impact factor: 4.090

4.  Increased survival disparities among children and adolescents & young adults with acute myeloid leukemia: A Dutch population-based study.

Authors:  Maya Schulpen; Bianca F Goemans; Gertjan J L Kaspers; Marc H G P Raaijmakers; C Michel Zwaan; Henrike E Karim-Kos
Journal:  Int J Cancer       Date:  2021-12-16       Impact factor: 7.316

5.  Pediatric cancer mortality and survival in the United States, 2001-2016.

Authors:  David A Siegel; Lisa C Richardson; S Jane Henley; Reda J Wilson; Nicole F Dowling; Hannah K Weir; Eric W Tai; Natasha Buchanan Lunsford
Journal:  Cancer       Date:  2020-07-29       Impact factor: 6.921

6.  Cytogenetic and mutational analysis and outcome assessment of a cohort of 284 children with de novo acute myeloid leukemia reveal complex karyotype as an adverse risk factor for inferior survival.

Authors:  Xi Chen; Xingjuan Wang; Hu Dou; Zhenzhen Yang; Junqin Bi; Yi Huang; Ling Lu; Jie Yu; Liming Bao
Journal:  Mol Cytogenet       Date:  2021-05-19       Impact factor: 2.009

Review 7.  Straight to the Point-The Novel Strategies to Cure Pediatric AML.

Authors:  Monika Lejman; Izabela Dziatkiewicz; Mateusz Jurek
Journal:  Int J Mol Sci       Date:  2022-02-10       Impact factor: 5.923

8.  Effect of MT2A on apoptosis and proliferation in HL60 cells.

Authors:  Yu-Qing Pan; Min Niu; Shu-Min Liu; Yu-Xia Bao; Kai Yang; Xiao-Bo Ma; Liang He; Yi-Xun Li; Jie-Xian Cao; Xi Zhang; Yan Du
Journal:  Int J Med Sci       Date:  2021-06-04       Impact factor: 3.738

9.  Risk-associated alterations in marrow T cells in pediatric leukemia.

Authors:  Jithendra Kini Bailur; Samuel S McCachren; Katherine Pendleton; Juan C Vasquez; Hong Seo Lim; Alyssa Duffy; Deon B Doxie; Akhilesh Kaushal; Connor Foster; Deborah DeRyckere; Sharon Castellino; Melissa L Kemp; Peng Qiu; Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  JCI Insight       Date:  2020-08-20

10.  A compound combination screening approach with potential to identify new treatment options for paediatric acute myeloid leukaemia.

Authors:  Katrina M Lappin; Lindsay Davis; Kyle B Matchett; Yubin Ge; Ken I Mills; Jaine K Blayney
Journal:  Sci Rep       Date:  2020-10-28       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.